Stream Bio launches Conjugated Polymer Nanoparticles worldwide with Sigma Aldrich

Stream Bio, a company that develops and manufactures a range of revolutionary bioimaging molecular probes, is delighted to announce that its Conjugated Polymer Nanoparticles (CPNs™) are now available to purchase worldwide through Sigma Aldrich.

The news represents another significant step forward for the company, enabling a wide range of users across the world to purchase these highly fluorescent, non-toxic molecular probes. This will cement the company’s place as a global leader in the conjugated polymer nanoparticles market and facilitate the use of their technology throughout the evolving bioimaging field.

Stream Bio’s CPNs have applications in diagnostics and therapeutics, with the potential to be used for imaging tumours and fluorescence-guided surgery. These highly fluorescent, non-toxic nanoparticles are set to transform the bioimaging market with their unique brightness, exceptional stability, magnetic capability and suitability for conjugation with a wide range of molecules.

Currently, CPNs are available in four wavelengths; 475nm, 510nm, 550nm and 680nm. They can also be purchased in a conjugated form, with fluorescent streptavidin covalently attached. This enables them to be used in different protocols for the detection of a variety of proteins, protein motifs, nucleic acids, and other biomolecules.

Initially, a small range of unconjugated CPNs will be available to purchase from Sigma Aldrich, with a wider range of products soon to be included in the listing.

Steve Self, Commercial Director at Stream Bio, said: “The listing by Sigma Aldrich is an important step in terms of making our CPN technology available to a wider user base. We are excited to have many new products in the pipeline, which will broaden the application of our technology by spanning into the NIR region. In addition, a variety of new surface chemistries are also in development. We hope that this is the first of many collaborations with Sigma Aldrich and the Merck Group.”

Andrew Chaloner, Founding Director and CEO of Stream Bio, commented: “We are delighted to be launching our range of CPNs with Sigma Aldrich. This has only been possible thanks to many years of hard work put in by the team here at Stream. I am excited to have our products available to a wider user base and I can’t wait to see what the future holds for our products.”

If you would like to work with Stream Bio on development projects and products where CPNs™ could enhance sensitivity or capabilities, please contact us.